Clinical trial
The Clinical Impact of 68Ga-DOTATATE PET in the Management of Patients With Neuroendocrine Tumors
NCT03873870 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Clinical Impact of 68Ga-DOTATATE PET in the Management of Patients With Neuroendocrine Tumors
- Lead sponsor
- University Health Network, Toronto
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 28, 2019
- Completion date
- April 30, 2023
- Enrollment
- 1,916 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.